Get inside Wall Avenue with StreetInsider Premium. Declare your 1-week free trial here.
SwanBio Therapeutics, a gene remedy firm advancing AAV-based therapies for the remedy of devastating, genetically outlined neurological situations, right now introduced that Marita James, CPA, has been appointed as the corporate’s Chief Monetary Officer. Ms. James, a seasoned government with greater than 30 years of monetary expertise, served as SwanBio’s interim Chief Monetary Officer since February 2020.
“Marita’s contributions have been instrumental to our enterprise and monetary progress, and we’re thrilled to have her be part of SwanBio on a full-time foundation,” mentioned Tom Anderson, Chief Govt Officer of SwanBio. “Our firm is quickly evolving as we broaden our portfolio of a number of gene remedy applications and advance our lead program, SBT101, by IND-enabling research for the remedy of adrenomyeloneuropathy. Crucial to our success will probably be leveraging the insights and expertise of our gifted workforce, and we look ahead to persevering with to profit from Marita’s important monetary administration experience as we execute the following part of our development and transition right into a scientific firm.”
“Since becoming a member of as interim CFO, I’ve seen this workforce in motion and noticed the promise that our applications maintain. I’m extremely impressed by this firm’s mission to develop therapies that stop illness development for folks with neurological issues,” mentioned Ms. James. “We now have made important progress throughout all points of our operations during the last 12 months, most notably with our AAV-based applications, which have the potential to deal with the basis reason behind illness. There are quite a few alternatives for our science and know-how, and I’m honored to proceed supporting SwanBio to advance our pipeline and firm.”
Ms. James brings intensive monetary expertise to SwanBio. Previous to her position as interim CFO, Ms. James was a monetary advisor to rising and established biotechnology corporations, serving to to guide monetary technique and total enterprise operations. Earlier than consulting, she served as CFO of two world scientific analysis organizations, QPS Group Holdings, LLC and Frontage Laboratories, Inc., the place she helped information every group from preclinical by late-stage trials and oversaw double-digit income development. Earlier, Ms. James served in funding banking roles at MMCO Consulting, LLC, and Howard, Lawson & Co., LLC. She started her profession in public accounting at PricewaterhouseCoopers. Ms. James is an authorized public accountant and holds an M.S. in. utilized constructive psychology from the College of Pennsylvania and a B.A. in accounting from LaSalle College.
About SwanBio Therapeutics
SwanBio Therapeutics is a gene remedy firm that goals to deliver life-changing therapies to folks with devastating, genetically outlined neurological situations. SwanBio is advancing a pipeline of AAV-based gene therapies, designed to be delivered intrathecally, that may handle targets inside each the central and peripheral nervous programs. This strategy has the potential to be utilized broadly throughout three illness classifications – spastic paraplegias, monogenic neuropathies and polygenic neuropathies. SwanBio’s lead program is being superior towards scientific growth for the remedy of adrenomyeloneuropathy (AMN). For extra data, go to SwanBioTx.com.
Supply: SwanBio Therapeutics